Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
What the film says
When B-cell lymphoma comes back after CAR T therapy, one common reason is that the cancer drops the target, CD19, from its surface.
The idea: aim at two targets at once, and build the cells faster, in the hospital that treats the patient.
At the Medical College of Wisconsin, a patient's T cells receive a receptor that recognizes both CD19 and CD20. They are grown on site in eight to twelve days, not shipped away for weeks, with interleukin-7 and -15 to keep younger, longer-lasting cells.
In seventeen patients with relapsed mantle cell lymphoma, every one responded, and eighty-eight percent completely.
Nirav Shah leads the trial in Milwaukee, now extending to other lymphomas, CLL, and lymphoma in the brain. Public record; not medical advice.
Sources behind this film
Zurko JC. Cytotherapy, 2022
Relapse after CD19 CAR T via antigen loss
Shah NN. J Clin Oncol, 2025
Dual CD20/CD19 receptor; On-site manufacture, 8–12 days, CliniMACS Prodigy; IL-7/IL-15 expansion; naïve / stem-cell-memory-like T cells; 17 relapsed MCL patients: ORR 100%, CR 88%
Dual CD20/CD19 receptor; On-site manufacture, 8–12 days, CliniMACS Prodigy; IL-7/IL-15 expansion; naïve / stem-cell-memory-like T cells; Nirav Shah; Milwaukee; NHL, CLL, CNS lymphoma cohorts
The drug
A fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
A fixed cryopreserved dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
This is a Phase 1/Phase 2 study. The objectives are as follows: 1. Phase 1: Determine the safety of a fixed dose of 2.5x10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15 in relapsed refractory B-cell NHL with flexible 8/12-day manufacturing and a fixed 12-day manufacturing process along with an evaluation in chronic lymphocytic leukemia (CLL) and central nervous system (CNS) lymphoma. 2. Phase 1b: Four arms: Arm A: 8/12 flexible manufacturing arm.
The study
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.